Literature DB >> 9179919

Inducible (type II) nitric oxide synthase in human placental villous tissue of normotensive, pre-eclamptic and intrauterine growth-restricted pregnancies.

L Myatt1, A L Eis, D E Brockman, W Kossenjans, I Greer, F Lyall.   

Abstract

We have utilized two distinct monospecific antibodies against the type II (macrophage or inducible) nitric oxide synthase (NOS) isoform to localize the distribution of the enzyme within the human placenta in tissues from normotensive pregnancies and those complicated by pre-eclampsia and/or intrauterine growth restriction. Both antibodies immunolocalize to cells in the villous stroma on frozen sections of villous tissue. Colocalization studies with anti-CD14 or anti-CD45 antibodies that recognize cells of leucocyte or monocyte/macrophage lineage indicate that Hofbauer cells are expressing type II NOS. This is in contrast to expression of type III (endothelial) NOS which is seen in syncytiotrophoblast and in villous vascular endothelium. In some, but not all, normotensive and pathologic placental tissue, some type II NOS immunostaining could be seen in syncytiotrophoblast and vascular endothelium; however, no differences could be discerned between groups of tissues. Expression of type II NOS by Hofbauer cells may indicate they are involved in surveillance against maternal immune insult or maternal pathogens whereby they secrete nitric oxide to exert a cytostatic/cytotoxic effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179919     DOI: 10.1016/s0143-4004(97)80060-4

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  16 in total

1.  NADPH-diaphorase activity and nitric oxide synthase isoforms in the trophoblast of Calomys callosus.

Authors:  N Moraes; D Zago; S Gagioti; M S Hoshida; E Bevilacqua
Journal:  J Anat       Date:  2001-04       Impact factor: 2.610

2.  In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies.

Authors:  T H Hung; J N Skepper; G J Burton
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  Tissue kallikrein in human placenta in early and late gestation.

Authors:  G Valdés; C Chacón; J Corthorn; C D Figueroa; A M Germain
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

4.  Glyceryl trinitrate inhibits hypoxia/reoxygenation-induced apoptosis in the syncytiotrophoblast of the human placenta: therapeutic implications for preeclampsia.

Authors:  Louiza Belkacemi; Shannon A Bainbridge; Michelle A Dickinson; Graeme N Smith; Charles H Graham
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

5.  N,N-Dimethylacetamide Significantly Attenuates LPS- and TNFα-Induced Proinflammatory Responses Via Inhibition of the Nuclear Factor Kappa B Pathway.

Authors:  Ryan Pekson; Vladimir Poltoratsky; Samir Gorasiya; Sruthi Sundaram; Charles R Ashby; Ivana Vancurova; Sandra E Reznik
Journal:  Mol Med       Date:  2016-10-24       Impact factor: 6.354

6.  Expression of nitric oxide synthase isoforms in pregnant human myometrium.

Authors:  S R Bartlett; P R Bennett; J S Campa; W J Dennes; D M Slater; G E Mann; L Poston; R Poston
Journal:  J Physiol       Date:  1999-12-15       Impact factor: 5.182

Review 7.  Protein nitration in placenta - functional significance.

Authors:  R P Webster; V H J Roberts; L Myatt
Journal:  Placenta       Date:  2008-10-11       Impact factor: 3.481

Review 8.  Oxidative stress in the placenta.

Authors:  Leslie Myatt; Xiaolan Cui
Journal:  Histochem Cell Biol       Date:  2004-07-10       Impact factor: 4.304

Review 9.  Role of nitric oxide in placental vascular development and function.

Authors:  B J Krause; M A Hanson; P Casanello
Journal:  Placenta       Date:  2011-07-27       Impact factor: 3.481

10.  The importance of cysteine cathepsin proteases for placental development.

Authors:  Aikaterini Varanou; Sarah L Withington; Lorin Lakasing; Catherine Williamson; Graham J Burton; Myriam Hemberger
Journal:  J Mol Med (Berl)       Date:  2006-01-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.